The Ceprotin Treatment Registry, sponsored by Baxalta (now part of Shire), aims to gather comprehensive data on the treatment and safety outcomes of patients with severe congenital Protein C deficiency receiving Ceprotin. Given the rarity of this condition, the registry serves as a critical tool for understanding treatment efficacy and safety, potentially enhancing market positioning for Ceprotin in the niche coagulation disorder space. The completion of this observational study may provide valuable insights for future product development and regulatory submissions, while also reinforcing Shire's commitment to rare disease management. The competitive landscape includes other therapies targeting coagulation disorders, necessitating ongoing vigilance regarding emerging treatments and market entrants.